Levosimendan
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ventricular Dysfunction, Left
Conditions
Ventricular Dysfunction, Left, Hip Fracture
Trial Timeline
May 1, 2014 → Apr 1, 2019
NCT ID
NCT02972918About Levosimendan
Levosimendan is a pre-clinical stage product being developed by Orion Corporation for Ventricular Dysfunction, Left. The current trial status is completed. This product is registered under clinical trial identifier NCT02972918. Target conditions include Ventricular Dysfunction, Left, Hip Fracture.
What happened to similar drugs?
2 of 11 similar drugs in Ventricular Dysfunction, Left were approved
Approved (2) Terminated (2) Active (7)
Hype Score Breakdown
Clinical
3
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05664191 | Phase 2 | Recruiting |
| NCT03948178 | Phase 3 | Terminated |
| NCT02972918 | Pre-clinical | Completed |
| NCT01101620 | Pre-clinical | Completed |
| NCT00130884 | Phase 2 | Completed |
| NCT00130871 | Phase 2 | Completed |
| NCT00219388 | Approved | Completed |
| NCT00048425 | Phase 3 | Completed |
Competing Products
20 competing products in Ventricular Dysfunction, Left